Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment

Objectives: Although recognized for decades, little is known about the etiology, physiopathology, and prevention of persistent pulmonary hypertension of the newborn (PPHN), and its treatment remains a major challenge for neonatologists. In this review, the clinical features and physiopathology of th...

Full description

Bibliographic Details
Main Authors: Joaquim E.B. Cabral, Jaques Belik
Format: Article
Language:English
Published: Elsevier 2013-05-01
Series:Jornal de Pediatria
Online Access:http://www.sciencedirect.com/science/article/pii/S0021755713000594
id doaj-63c08d17226f457493daaaa91cc8b0f7
record_format Article
spelling doaj-63c08d17226f457493daaaa91cc8b0f72020-11-24T21:20:12ZengElsevierJornal de Pediatria0021-75572013-05-01893226242Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatmentJoaquim E.B. Cabral0Jaques Belik1Neonatologist, Hospital São Luiz, São Paulo, SP, Brazil; Corresponding author.Neonatologist. Professor of Pediatrics and Physiology, University of Toronto, The Hospital for Sick Children, Toronto, CanadaObjectives: Although recognized for decades, little is known about the etiology, physiopathology, and prevention of persistent pulmonary hypertension of the newborn (PPHN), and its treatment remains a major challenge for neonatologists. In this review, the clinical features and physiopathology of the syndrome will be addressed, as well as its general and specific treatments. Data source: A review was carried out in PubMed, Cochrane Library, and MRei consult databases, searching for articles related to the syndrome and published between 1995 and 2011. Data synthesis: Risk factors and the physiopathological mechanisms of the syndrome are discussed. The clinical presentation depends on the different factors involved. These are related to the etiology and physiopathology of the different forms of the disease. In addition to the measures used to allow for the decrease in pulmonary vascular resistance after birth, in some instances pulmonary vasodilators will be required. Although inhaled nitric oxide has proved effective, other vasodilators have been recently used, but clinical evidence is still lacking to demonstrate their benefits in the treatment of PPHN. Conclusions: Despite recent technological advances and new physiopathological knowledge of this disease, mortality associated with PPHN remains at 10%. More clinical research and evidence-based experimental results are needed to prevent, treat, and reduce the morbidity/mortality associated with this neonatal syndrome. Resumo: Objetivos: Embora reconhecida há décadas, ainda pouco se sabe a respeito da etiologia, fisiopatologia e prevenção da hipertensão pulmonar persistente neonatal (HPPN), e seu tratamento continua a ser um grande desafio para os neonatologistas. Nesta revisão, vamos abordar as características clínicas e os mecanismos fisiopatológicos da síndrome, assim como seu tratamento geral e específico. Fontes de dados: Fizemos uma revisão nas bases de dados PubMed, Cochrane Library e MRei Consult, procurando por artigos relacionados à síndrome e publicados entre 1995e 2011. Síntese de dados: São discutidos os fatores de risco e os mecanismos fisiopatológicos da síndrome. O quadro clínico depende dos diferentes fatores envolvidos, que provavelmente estão relacionados com a etiologia e o mecanismo fisiopatológico. Além das medidas utilizadas para permitir a queda da resistência vascular pulmonar após o nascimento, alguns casos necessitam de vasodilatadores pulmonares. Embora o óxido nítrico tenha se provado efetivo, recentemente, outros vasodilatadores têm sido usados, mas ainda faltam evidências clínicas para comprovar seus benefícios no tratamento da HPPN. Conclusões: Apesar dos recentes avanços tecnológicos e dos novos conhecimentos fisiopatológicos, a mortalidade associada à HPPN ainda é de 10%. São necessárias mais pesquisas clínicas e resultados experimentais baseados em evidências para prevenir, tratar e reduzir a morbimortalidade associada a esta síndrome neonatal. Keywords: Pulmonary hypertension, Pulmonary vasodilators, Nitric oxide, Palavras-chave: Hipertensão pulmonar, Vasodilatadores pulmonares, Óxido nítricohttp://www.sciencedirect.com/science/article/pii/S0021755713000594
collection DOAJ
language English
format Article
sources DOAJ
author Joaquim E.B. Cabral
Jaques Belik
spellingShingle Joaquim E.B. Cabral
Jaques Belik
Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment
Jornal de Pediatria
author_facet Joaquim E.B. Cabral
Jaques Belik
author_sort Joaquim E.B. Cabral
title Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment
title_short Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment
title_full Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment
title_fullStr Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment
title_full_unstemmed Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment
title_sort persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment
publisher Elsevier
series Jornal de Pediatria
issn 0021-7557
publishDate 2013-05-01
description Objectives: Although recognized for decades, little is known about the etiology, physiopathology, and prevention of persistent pulmonary hypertension of the newborn (PPHN), and its treatment remains a major challenge for neonatologists. In this review, the clinical features and physiopathology of the syndrome will be addressed, as well as its general and specific treatments. Data source: A review was carried out in PubMed, Cochrane Library, and MRei consult databases, searching for articles related to the syndrome and published between 1995 and 2011. Data synthesis: Risk factors and the physiopathological mechanisms of the syndrome are discussed. The clinical presentation depends on the different factors involved. These are related to the etiology and physiopathology of the different forms of the disease. In addition to the measures used to allow for the decrease in pulmonary vascular resistance after birth, in some instances pulmonary vasodilators will be required. Although inhaled nitric oxide has proved effective, other vasodilators have been recently used, but clinical evidence is still lacking to demonstrate their benefits in the treatment of PPHN. Conclusions: Despite recent technological advances and new physiopathological knowledge of this disease, mortality associated with PPHN remains at 10%. More clinical research and evidence-based experimental results are needed to prevent, treat, and reduce the morbidity/mortality associated with this neonatal syndrome. Resumo: Objetivos: Embora reconhecida há décadas, ainda pouco se sabe a respeito da etiologia, fisiopatologia e prevenção da hipertensão pulmonar persistente neonatal (HPPN), e seu tratamento continua a ser um grande desafio para os neonatologistas. Nesta revisão, vamos abordar as características clínicas e os mecanismos fisiopatológicos da síndrome, assim como seu tratamento geral e específico. Fontes de dados: Fizemos uma revisão nas bases de dados PubMed, Cochrane Library e MRei Consult, procurando por artigos relacionados à síndrome e publicados entre 1995e 2011. Síntese de dados: São discutidos os fatores de risco e os mecanismos fisiopatológicos da síndrome. O quadro clínico depende dos diferentes fatores envolvidos, que provavelmente estão relacionados com a etiologia e o mecanismo fisiopatológico. Além das medidas utilizadas para permitir a queda da resistência vascular pulmonar após o nascimento, alguns casos necessitam de vasodilatadores pulmonares. Embora o óxido nítrico tenha se provado efetivo, recentemente, outros vasodilatadores têm sido usados, mas ainda faltam evidências clínicas para comprovar seus benefícios no tratamento da HPPN. Conclusões: Apesar dos recentes avanços tecnológicos e dos novos conhecimentos fisiopatológicos, a mortalidade associada à HPPN ainda é de 10%. São necessárias mais pesquisas clínicas e resultados experimentais baseados em evidências para prevenir, tratar e reduzir a morbimortalidade associada a esta síndrome neonatal. Keywords: Pulmonary hypertension, Pulmonary vasodilators, Nitric oxide, Palavras-chave: Hipertensão pulmonar, Vasodilatadores pulmonares, Óxido nítrico
url http://www.sciencedirect.com/science/article/pii/S0021755713000594
work_keys_str_mv AT joaquimebcabral persistentpulmonaryhypertensionofthenewbornrecentadvancesinpathophysiologyandtreatment
AT jaquesbelik persistentpulmonaryhypertensionofthenewbornrecentadvancesinpathophysiologyandtreatment
_version_ 1726003461688918016